Newsletter July 2025

Panel Screening Opportunity in TNBC Models

Decorative image: Newsletter July 2025

Dear Colleagues, 

we’re offering a unique opportunity to evaluate your compound across a panel of 14 well-characterized triple-negative breast cancer (TNBC) models. This joint screening initiative enables you to benefit from shared controls, streamlined workflows, and competitive pricing — all while generating robust, translatable efficacy data. Optional add-on services such as IHC, PK/PD, and histology are also available to deepen your insights. EPO’s expertise in TNBC modeling and drug evaluation was recently featured in an oral presentation at AACR 2025 [Abstract] highlighting our leadership in translational oncology research.

Read

Test the efficacy of your compound(s) in a panel of 14 TNBC PDX models

Enrollment is now open through August 15th

FEATURES

  • Access to a curated panel of 14 well-characterized triple-negative breast cancer (TNBC) models, representing diverse molecular and phenotypic profiles.
  • Each model is backed by RNA sequencing data, mutations and tissue bank samplesModels have been pre-tested with clinically relevant compounds
  • Standardized 8-week study duration, with tumor growth inhibition as the primary efficacy read-out
  • Competitive pricing available when selecting the full 14-model panel screen, leveraging shared controls and streamlined workflows for maximum value.
  • Option to include additional services such as IHC, PK/PD, and histology and sampling (frozen, FFPE, blood) tailored to support deeper mechanistic insights and biomarker discovery

Please contact us directly to discuss your compound of interest, reserve your slot, or request a detailed study proposal.

Best regards,

Jens Hoffmann (CEO), Wolfgang Walther (CSO), Antje Wengner (CSO) EPO Berlin-Buch

Decorative image: Newsletter July 2025

Related Talks and Publications

Talk AACR, Chicago 2025

  • Triple negative breast cancer (TNBC) PDX models for preclinical investigation of novel therapies
    Hoffmann J, Behrens D
    Abstract

Publications

  • Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
    Heynen GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, Alcaniz J, Montaudon E, Marangoni E, Birchmeier W. Breast
    Cancer Res. 2022;24(1):23 (Weblink)
  • MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
    Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M.
    Breast Cancer Res. 2019;21(1):20 (Weblink)